Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation

Alisha Y. Young; Miguel M. Leiva Juarez; Scott E. Evans

doi:10.1016/j.ccm.2017.04.009

Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation

Alisha Y. Young, Miguel M. Leiva Juarez, Scott E. Evans

Pulmonary Medicine

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Fungal pneumonias cause unacceptable morbidity among patients with hematologic malignancies (HM) and recipients of hematopoietic stem cell transplantation (HSCT). The high incidence of fungal pneumonias in HM/HSCT populations arises from their frequently severe, complex, and persistent immune dysfunction caused by the underlying disease and its treatment. The cytopenias, treatment toxicities, and other immune derangements that make patients susceptible to fungal pneumonia frequently complicate its diagnosis and increase the intensity and duration of antifungal therapy. This article addresses the host factors that contribute to susceptibility, summarizes diagnostic recommendations, and reviews current guidelines for management of fungal pneumonia in patients with HM/HSCT.

Original language	English (US)
Pages (from-to)	479-491
Number of pages	13
Journal	Clinics in Chest Medicine
Volume	38
Issue number	3
DOIs	https://doi.org/10.1016/j.ccm.2017.04.009
State	Published - Sep 2017

Keywords

Fungal pneumonia
Galactomannan
Hematologic malignancy
Immunocompromised host pneumonia
Neutropenia
Stem cell transplant

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.ccm.2017.04.009

Cite this

@article{2d80cab88c86456a9784846188f93959,

title = "Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation",

abstract = "Fungal pneumonias cause unacceptable morbidity among patients with hematologic malignancies (HM) and recipients of hematopoietic stem cell transplantation (HSCT). The high incidence of fungal pneumonias in HM/HSCT populations arises from their frequently severe, complex, and persistent immune dysfunction caused by the underlying disease and its treatment. The cytopenias, treatment toxicities, and other immune derangements that make patients susceptible to fungal pneumonia frequently complicate its diagnosis and increase the intensity and duration of antifungal therapy. This article addresses the host factors that contribute to susceptibility, summarizes diagnostic recommendations, and reviews current guidelines for management of fungal pneumonia in patients with HM/HSCT.",

keywords = "Fungal pneumonia, Galactomannan, Hematologic malignancy, Immunocompromised host pneumonia, Neutropenia, Stem cell transplant",

author = "Young, {Alisha Y.} and {Leiva Juarez}, {Miguel M.} and Evans, {Scott E.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = sep,

doi = "10.1016/j.ccm.2017.04.009",

language = "English (US)",

volume = "38",

pages = "479--491",

journal = "Clinics in Chest Medicine",

issn = "0272-5231",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation

AU - Young, Alisha Y.

AU - Leiva Juarez, Miguel M.

AU - Evans, Scott E.

PY - 2017/9

Y1 - 2017/9

N2 - Fungal pneumonias cause unacceptable morbidity among patients with hematologic malignancies (HM) and recipients of hematopoietic stem cell transplantation (HSCT). The high incidence of fungal pneumonias in HM/HSCT populations arises from their frequently severe, complex, and persistent immune dysfunction caused by the underlying disease and its treatment. The cytopenias, treatment toxicities, and other immune derangements that make patients susceptible to fungal pneumonia frequently complicate its diagnosis and increase the intensity and duration of antifungal therapy. This article addresses the host factors that contribute to susceptibility, summarizes diagnostic recommendations, and reviews current guidelines for management of fungal pneumonia in patients with HM/HSCT.

AB - Fungal pneumonias cause unacceptable morbidity among patients with hematologic malignancies (HM) and recipients of hematopoietic stem cell transplantation (HSCT). The high incidence of fungal pneumonias in HM/HSCT populations arises from their frequently severe, complex, and persistent immune dysfunction caused by the underlying disease and its treatment. The cytopenias, treatment toxicities, and other immune derangements that make patients susceptible to fungal pneumonia frequently complicate its diagnosis and increase the intensity and duration of antifungal therapy. This article addresses the host factors that contribute to susceptibility, summarizes diagnostic recommendations, and reviews current guidelines for management of fungal pneumonia in patients with HM/HSCT.

KW - Fungal pneumonia

KW - Galactomannan

KW - Hematologic malignancy

KW - Immunocompromised host pneumonia

KW - Neutropenia

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=85019974354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019974354&partnerID=8YFLogxK

U2 - 10.1016/j.ccm.2017.04.009

DO - 10.1016/j.ccm.2017.04.009

M3 - Review article

C2 - 28797490

AN - SCOPUS:85019974354

SN - 0272-5231

VL - 38

SP - 479

EP - 491

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

IS - 3

ER -

Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this